186 related articles for article (PubMed ID: 25314575)
1. The truncate mutation of Notch2 enhances cell proliferation through activating the NF-κB signal pathway in the diffuse large B-cell lymphomas.
Zhang X; Shi Y; Weng Y; Lai Q; Luo T; Zhao J; Ren G; Li W; Pan H; Ke Y; Zhang W; He Q; Wang Q; Zhou R
PLoS One; 2014; 9(10):e108747. PubMed ID: 25314575
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma.
Lee SY; Kumano K; Nakazaki K; Sanada M; Matsumoto A; Yamamoto G; Nannya Y; Suzuki R; Ota S; Ota Y; Izutsu K; Sakata-Yanagimoto M; Hangaishi A; Yagita H; Fukayama M; Seto M; Kurokawa M; Ogawa S; Chiba S
Cancer Sci; 2009 May; 100(5):920-6. PubMed ID: 19445024
[TBL] [Abstract][Full Text] [Related]
3. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
[TBL] [Abstract][Full Text] [Related]
4. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
6. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
[No Abstract] [Full Text] [Related]
7. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
Kim SW; Oleksyn DW; Rossi RM; Jordan CT; Sanz I; Chen L; Zhao J
Blood; 2008 Feb; 111(3):1644-53. PubMed ID: 18025152
[TBL] [Abstract][Full Text] [Related]
8. CD40L-mediated inhibition of NF-kappaB in CA46 Burkitt lymphoma cells promotes apoptosis.
Wang S; Wang S; Yang T; Zhu F; Zhu J; Huang Y; Wu L; Chen L; Xu Z
Leuk Lymphoma; 2008 Sep; 49(9):1792-9. PubMed ID: 18661398
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
10. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
[TBL] [Abstract][Full Text] [Related]
11. Effect of notch1,2,3 genes silicing on NF-κB signaling pathway of macrophages in patients with atherosclerosis.
Ruan ZB; Fu XL; Li W; Ye J; Wang RZ; Zhu L
Biomed Pharmacother; 2016 Dec; 84():666-673. PubMed ID: 27697639
[TBL] [Abstract][Full Text] [Related]
12. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.
Qu C; Liu Y; Kunkalla K; Singh RR; Blonska M; Lin X; Agarwal NK; Vega F
Blood; 2013 Jun; 121(23):4718-28. PubMed ID: 23632891
[TBL] [Abstract][Full Text] [Related]
13. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
[TBL] [Abstract][Full Text] [Related]
14. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
15. An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression.
Zhang B; Calado DP; Wang Z; Fröhler S; Köchert K; Qian Y; Koralov SB; Schmidt-Supprian M; Sasaki Y; Unitt C; Rodig S; Chen W; Dalla-Favera R; Alt FW; Pasqualucci L; Rajewsky K
Cell Rep; 2015 May; 11(5):715-26. PubMed ID: 25921526
[TBL] [Abstract][Full Text] [Related]
16. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.
Habineza Ndikuyeze G; Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Flood P; Krick E; Propert KJ; Mason NJ
PLoS One; 2014; 9(5):e95404. PubMed ID: 24798348
[TBL] [Abstract][Full Text] [Related]
18. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.
Rossi D; Trifonov V; Fangazio M; Bruscaggin A; Rasi S; Spina V; Monti S; Vaisitti T; Arruga F; Famà R; Ciardullo C; Greco M; Cresta S; Piranda D; Holmes A; Fabbri G; Messina M; Rinaldi A; Wang J; Agostinelli C; Piccaluga PP; Lucioni M; Tabbò F; Serra R; Franceschetti S; Deambrogi C; Daniele G; Gattei V; Marasca R; Facchetti F; Arcaini L; Inghirami G; Bertoni F; Pileri SA; Deaglio S; Foà R; Dalla-Favera R; Pasqualucci L; Rabadan R; Gaidano G
J Exp Med; 2012 Aug; 209(9):1537-51. PubMed ID: 22891273
[TBL] [Abstract][Full Text] [Related]
19. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
[TBL] [Abstract][Full Text] [Related]
20. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
